JY
PYXS icon

Jeff Yass’s Pyxis Oncology PYXS Stock Holding History

Jeff Yass’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139K Buy
46,200
+3,900
+9% +$7.46K ﹤0.01% 12263
2026
Q1 		$61.8K Sell
42,300
-138,000
-77% -$208K ﹤0.01% 12564
2025
Q4 		$207K Buy
180,300
+158,800
+739% +$560K ﹤0.01% 10794
2025
Q3 		$47.7K Buy
+21,500
New +$31K ﹤0.01% 11875
2025
Q1 		– Sell
-832,200
Closed -$1.3M – 13261
2024
Q4 		$1.3M Buy
832,200
+808,400
+3,397% +$2.33M ﹤0.01% 6324
2024
Q3 		$87.3K Buy
23,800
+1,400
+6% +$4.9K ﹤0.01% 11130
2024
Q2 		$74.1K Sell
22,400
-12,500
-36% -$52.6K ﹤0.01% 11215
2024
Q1 		$149K Buy
34,900
+24,400
+232% +$103K ﹤0.01% 10911
2023
Q4 		$18.9K Sell
10,500
-13,100
-56% -$22.4K ﹤0.01% 11982
2023
Q3 		$47K Sell
23,600
-3,800
-14% -$8.8K ﹤0.01% 11329
2023
Q2 		$70.1K Buy
+27,400
New +$86.9K ﹤0.01% 11180

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's PYXS Position: Q2 2026 in Review

Jeff Yass sold out of Pyxis Oncology (PYXS) in Q2 2026, closing a stake of 41,201 shares — an estimated $78.8K sold.

Jeff Yass first reported a position in PYXS in Q2 2022 and held it in 13 quarters. The position peaked at $383K in Q2 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Jeff Yass reported no remaining Pyxis Oncology position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 41,201 Pyxis Oncology shares in Q2 2026, an estimated $78.8K.
  • Jeff Yass first reported a position in Pyxis Oncology in Q2 2022 and held it in 13 quarters.
  • Jeff Yass's Pyxis Oncology position peaked at $383K in Q2 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.